ClinicalTrials.gg
RecruitingNCT07640620Updated Jun 11, 2026

Relationship Between Central Sensitization and Clinical Features in Plantar Fasciitis

An observational study in Plantar Fasciitis, sponsored by Sultan Abdulhamid Han Training and Research Hospital, Istanbul, Turkey. Recruiting at 1 site in Turkey (Türkiye). Open to participants aged 18 Years to 65 Years, including healthy volunteers. Per ClinicalTrials.gov, last updated 2026-06-11.

Sponsored by Sultan Abdulhamid Han Training and Research Hospital, Istanbul, Turkey · Observational

From the registry’s dates

  • Started Apr 2026; still recruiting 7 months later.
Study type
Observational
Model
Case-control
Time perspective
Cross-sectional
Enrollment
128
Ages
18 Years to 65 Years
Sex
All
01

Study summary

Plantar fasciitis is a common cause of heel pain and is traditionally considered a mechanical musculoskeletal disorder. Recent evidence suggests that central sensitization may also contribute to pain in individuals with plantar fasciitis. This study aims to investigate the relationships between neurophysiological variables (pressure pain threshold, central sensitization, and pain intensity), psychological factors (pain catastrophizing, kinesiophobia, anxiety, and depression), ultrasonographic findings (plantar fascia thickness), and functional outcomes (foot function and quality of life) in patients with plantar fasciitis.

Read the detailed description

Heel pain caused by plantar fasciitis is one of the common reasons for visits to Physical Medicine and Rehabilitation outpatient clinics. Plantar fasciitis is characterized by throbbing medial plantar heel pain that occurs especially with the first step in the morning or after long periods of rest and is a musculoskeletal disorder. The diagnosis of plantar fasciitis is usually determined clinically. In ultrasound, findings such as thickening of the plantar fascia and hypoechogenicity in the fascia are advantageous in diagnosis. Although the mechanical aspect of pain has often been emphasized in the treatment of plantar fasciitis, recent studies have gained momentum in suggesting that central sensitization is also among the pain mechanisms of plantar fasciitis. In addition, as with many chronic musculoskeletal pains, the role of psychological factors such as kinesiophobia, catastrophizing pain, depressive symptoms, and anxiety has been investigated in plantar fasciitis. However, data on the relationship between factors such as pressure pain sensitivity, central sensitization, catastrophizing pain, and kinesiophobia in plantar fasciitis are limited. The aim of this study is to contribute to the increasing literature in this field by investigating the relationship between psychological (catastrophizing pain, kinesiophobia, anxiety, and depression), ultrasonographic findings (plantar fascia thickness), and functional status (foot functional index, quality of life) variables with neurophysiological (pressure pain threshold, central sensitization, pain) variables in plantar fasciitis.

02

Conditions studied

  • Plantar Fasciitis

Keywords

  • plantar fasciitis
  • central sensitization
  • pain pressure threshold
  • kinesiophobia
03

In context

Fasciitis, Plantar

223 studies on the registry are indexed under Fasciitis, Plantar; 58 are open to participants now.

This study's planned enrollment of 128 is above the median of 60 across 24 observational studies indexed under Fasciitis, Plantar.

Browse Fasciitis, Plantar studies →

Lead sponsor

Sultan Abdulhamid Han Training and Research Hospital, Istanbul, Turkey is the lead sponsor of 108 studies on the registry; 31 are open to participants now.

Counted across the registry records on this site, refreshed daily.

04

Who can participate

Ages eligible
18 Years to 65 Years
Sexes eligible
All
Accepts healthy volunteers
Yes
Sampling method
Non-probability sample

Study population

Individuals applying to the Physical Medicine and Rehabilitation Outpatient Clinic of Sultan 2. Abdülhamid Han Training and Research Hospital will be evaluated, and those who meet the inclusion criteria for the groups and sign the voluntary consent form will be included in the study.

Eligibility criteria

Plantar Fasciitis Group

  1. Inclusion criteria

    • Be between the ages of 18-65
    • Have unilateral heel pain that has been ongoing for at least 3 months, particularly worsening with the first few steps in the morning and increasing with weight-bearing activities throughout the day
    • Have tenderness on palpation of the medial calcaneal tubercle
    • Have read and signed the volunteer consent form (VCF)
  2. Exclusion criteria

    • Being under 18 years old or over 65 years old
    • Having a history of physical therapy, injection, radiation, or surgery targeting the plantar fascia within the last 6 months
    • Calcaneus fracture, tumor, or cyst related to the plantar fascia
    • Foot deformity (club foot, pes cavus, calcaneovalgus, etc.)
    • Lumbosacral radiculopathy, tarsal tunnel syndrome, peripheral neuropathy
    • Rheumatic diseases such as rheumatoid arthritis, ankylosing spondylitis, gout
    • Foot and ankle osteoarthritis
    • Presence of osteomyelitis or skin infection in the foot
    • Systemic diseases such as kidney and liver failure, diabetes, peripheral arterial vascular disease

Healthy Control

  1. Inclusion criteria

    • Being completely healthy
    • Being between the ages of 18 - 65
    • Having read and signed the volunteer consent form (BGOF)
  2. Exclusion criteria

    • Being under 18 or over 65 years old
    • Having any acute or chronic illness
    • Being illiterate and not giving consent to participate in the study
05

Study design

Observational model
Case-control
Time perspective
Cross-sectional
Enrollment
128 participants (estimated)
Patient registry
No

Groups and cohorts

  • Plantar fasciitis group

    Participants with clinically diagnosed plantar fasciitis.

    Other: Pressure Pain Threshold Assessment · Other: Ultrasonographic Assessment

  • Healthy Volunteers (control group)

    Age- and sex-matched healthy adults without plantar fasciitis.

    Other: Pressure Pain Threshold Assessment · Other: Ultrasonographic Assessment

Interventions

  • OtherPressure Pain Threshold Assessment

    Pressure pain threshold measurements will be performed using a pressure algometer to assess pain sensitivity.

  • OtherUltrasonographic Assessment

    Ultrasonographic evaluation will be performed to measure plantar fascia thickness and assess plantar fascia morphology.

06

What researchers measure

Primary outcomes

  1. Forearm Pressure Pain Threshold (PPT)

    Pressure pain threshold is defined as the minimal pressure level that causes pain. The measurement will be applied twice for each region with a 1-minute interval, and the average of these applications will be recorded. A trial test will be conducted on the patient before the actual test. Pressure will be applied to selected points with a pressure algometer until pain is induced, and the test for that area will be terminated when the patient feels pain. The measurement will be taken from the calcaneus bone (the starting point of the plantar fascia) and from the forearm, which is a distant, painless, and unrelated area, using the Wagner manual pressure algometer (1 cm² probe-10 kg/20 lb). The reliability of the measurement in these areas has been demonstrated.

    Time frame: Baseline

Secondary outcomes

  1. Numeric Pain Rating Scale, NPRS

    Pain severity will be evaluated using a scale rated from 0 (no pain) to 10 (unbearable pain). Participants will be asked to rate the pain felt with the first step after waking up in the morning and the average pain level over the past week.

    Time frame: Baseline

  2. Short Form-12 (SF-12)

    Physical Component Summary and Mental Component Summary

    Time frame: Baseline

  3. Foot Function Index

    The Foot Function Index is a self-report-based scale developed to evaluate the effects of foot and ankle-related problems on pain, functional limitation, and daily life activities in individuals, with its validity and reliability demonstrated. AFI consists of three sub-dimensions: pain, disability (functional limitation), and activity limitation. The scale allows individuals to evaluate foot-related problems they have experienced recently in the context of daily life activities. Each sub-dimension and total score reflect the level of impairment in foot functions. Increasing AFI scores indicate that the severity of foot pain and the limitations in foot functions have increased, thereby negatively affecting foot-related quality of life. AFI is widely used in clinical and research settings to evaluate the functional effects of foot pathologies.

    Time frame: Baseline

  4. Pain Catastrophizing Scale

    It is a valid and reliable self-report scale developed to assess individuals' exaggerated negative thoughts and emotional responses toward their pain experience. The scale measures cognitive and emotional responses that occur during or following pain and consists of three sub-dimensions: rumination (excessive focus on pain), magnification (exaggeration of the threatening consequences of pain), and helplessness.

    Time frame: Baseline

  5. Tampa Scale for Kinesiophobia

    It is a valid and reliable self-report scale developed to assess individuals' fear and avoidance behaviors toward movement and physical activity. The scale measures the level of fear of movement (kinesiophobia) that develops based on the belief that pain will reoccur or worsen.

    Time frame: Baseline

  6. Central Sensitization Inventory

    The central sensitization scale is a tool used to assess the hypersensitivity of the central nervous system. This scale includes questions that examine individuals' pain perception and its effects on daily life to detect the effects of central sensitization, which are generally observed in chronic pain conditions. The scale evaluates how individuals perceive pain in response to physical contact or other stimuli (pain sensitivity), changes in their sensitivity to heat, cold, or pressure (sensory changes), how the persistence of pain affects their daily activities, and the impact of pain on their emotional state (anxiety, depression, etc.).

    Time frame: Baseline

  7. Thickness of the plantar fascia in ultrasonographic imaging

    In the study, the evaluation with ultrasound will be conducted while the participants are in a prone position on the examination table, with their feet hanging off the table and in a dorsiflexed position. A linear probe will be placed longitudinally over the medial tubercle of the calcaneus to ultrasonographically examine the plantar fascia thickness (PFT). PFK will be measured 1 cm distal to the calcaneus attachment point. A PFK of 4 mm or greater will be considered evidence of fasciitis. It has been shown that this measurement technique has good intra-rater reliability. The Sonosite M-Turbo device will be used for ultrasonography and will be performed by a physical therapy and rehabilitation specialist with 10 years of experience.

    Time frame: Baseline

  8. Hospital Anxiety and Depression Scale

    It is a 14-item self-report scale that quickly, reliably, and independently of medical conditions assesses patients' anxiety and depression symptoms over the past week.

    Time frame: CROSS-SECTIONAL

  9. Weight-Bearing Lunge Test

    The range of motion of ankle dorsiflexion will be evaluated under load. The participant will be asked to keep their heel in contact with the ground and move their knee toward the wall, and the maximum distance between the thumb and the wall will be recorded in centimeters.

    Time frame: Baseline

  10. FOOT POSTURE INDEX

    The participant's foot will be observationally scored based on six anatomical criteria in a standing natural posture, and the total score will be recorded.

    Time frame: Baseline

07

Study locations

1 of 1 sites recruiting
08

References and documents

Publications

  • Jayaseelan DJ, Fernandez-de-Las-Penas C, Blattenberger T, Bonneau D. Altered Central Pain Processing in Patients With Chronic Plantar Heel Pain: A Critically Appraised Topic. J Sport Rehabil. 2021 Feb 16;30(5):812-817. doi: 10.1123/jsr.2020-0371. PubMed 33596547 ↗
  • Nijs J, Malfliet A, Nishigami T. Nociplastic pain and central sensitization in patients with chronic pain conditions: a terminology update for clinicians. Braz J Phys Ther. 2023 May-Jun;27(3):100518. doi: 10.1016/j.bjpt.2023.100518. Epub 2023 Jun 14. No abstract available. PubMed 37348359 ↗
  • Plaza-Manzano G, Rios-Leon M, Martin-Casas P, Arendt-Nielsen L, Fernandez-de-Las-Penas C, Ortega-Santiago R. Widespread Pressure Pain Hypersensitivity in Musculoskeletal and Nerve Trunk Areas as a Sign of Altered Nociceptive Processing in Unilateral Plantar Heel Pain. J Pain. 2019 Jan;20(1):60-67. doi: 10.1016/j.jpain.2018.08.001. Epub 2018 Aug 16. PubMed 30121357 ↗
  • Cotchett M, Lennecke A, Medica VG, Whittaker GA, Bonanno DR. The association between pain catastrophising and kinesiophobia with pain and function in people with plantar heel pain. Foot (Edinb). 2017 Aug;32:8-14. doi: 10.1016/j.foot.2017.03.003. Epub 2017 Mar 20. PubMed 28605621 ↗
  • Bennell KL, Talbot RC, Wajswelner H, Techovanich W, Kelly DH, Hall AJ. Intra-rater and inter-rater reliability of a weight-bearing lunge measure of ankle dorsiflexion. Aust J Physiother. 1998;44(3):175-180. doi: 10.1016/s0004-9514(14)60377-9. PubMed 11676731 ↗
  • Redmond AC, Crosbie J, Ouvrier RA. Development and validation of a novel rating system for scoring standing foot posture: the Foot Posture Index. Clin Biomech (Bristol). 2006 Jan;21(1):89-98. doi: 10.1016/j.clinbiomech.2005.08.002. Epub 2005 Sep 21. PubMed 16182419 ↗
  • Sabir N, Demirlenk S, Yagci B, Karabulut N, Cubukcu S. Clinical utility of sonography in diagnosing plantar fasciitis. J Ultrasound Med. 2005 Aug;24(8):1041-8. doi: 10.7863/jum.2005.24.8.1041. PubMed 16040817 ↗

Individual participant data

Plan to share: No — Individual participant data collected during this study will not be made available to other researchers.

09

Updates

Tracking since Sep 25, 2026
No changes since tracking began. The registry record was last updated on Jun 11, 2026, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT07640620
Responsible party
Feyza Nur Yucel (Associate Professor, Sultan Abdulhamid Han Training and Research Hospital, Istanbul, Turkey) — Principal investigator
First posted
Jun 11, 2026
Start date
Apr 7, 2026
Primary completion
Sep 20, 2026 (estimated)
Completion
Sep 20, 2026 (estimated)
Last update
Jun 11, 2026

Study contacts

Feyza Nur Yücel, Assoc. Prof.
Contact
dr.fny28@gmail.com
2165422000 ext. +90
Feyza Nur Yücel
principal investigator · Saglik Bilimleri Universitesi

Oversight

Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Interested in this study?

Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.

Contact study team

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion